MicroVue™ iC3b EIA
The MicroVue iC3b Assay is enzyme immunoassay for the quantitation of iC3b fragment of C3 protein.
Product Specifications
Citations | 12 |
---|---|
Specimen |
Serum/EDTA or Heparin Plasma 100 μL |
LLOQ | N/A |
ULOQ | N/A |
Assay Time | 1.5 hours |
Cross Reactivity |
None |
Ordering Information
Catalog Number | A006 |
---|---|
Catalog Number (CE) | |
Size | 96 wells/test |
Price (USD) | $725.00 |
Price (EURO) | 640,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
The MicroVue iC3b Assay is enzyme immunoassay for the quantitation of iC3b fragment of C3 protein. |
---|---|
Size | 96 wells/test |
Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
Specimen | Serum/EDTA or Heparin Plasma 100 μL |
Limit of Detection (LOD) | N/A |
Lower Limit of Quantitation (LLOQ) | N/A |
Upper Limit of Quantitation (ULOQ) | N/A |
Intra Assay | N/A |
Inter Assay | N/A |
Standards | 3 |
Controls | 2 |
Sample Values |
None |
Assay Time | 1.5 hours |
Cross Reactivity |
None |
Storage |
Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details. |
Background |
The Quidel iC3b Enzyme Immunoassay measures the amount of the iC3b present in samples. Activation of either complement pathway results in the assembly of C3 convertases that cleave C3 into two fragments – C3a and C3b. The C3a fragment is one of the complement anaphylatoxins. The C3b fragment has many important biological activities, including the promotion of phagocytosis by opsonization and participation as a structural component in C3 and C5 convertases. These biological activities of C3b are under stringent control in vivo. One mechanism limiting the in vivo lifetime of C3b involves the two-site cleavage of C3b by Factor I5 with the cooperation of Factor H6 or CR17 as cofactors. Factor H is a complement control protein. CR1 is the C3b/C4b receptor found on many cell types, including red blood cells, granulocytes, monocytes, and macrophages. Factor I two-site cleavage of C3b yields inactivated C3b, called iC3b. The biological activities of C3b are lost when it is cleaved by Factor I. iC3b fragments, either in fluid phase or bound to biological surfaces, express new biological activities due to their ability to interact with CR2 and CR3 receptors on a variety of cell types. The levels of iC3b can be significantly elevated in the serum and plasma of some patients with immune complex-associated diseases such as rheumatoid arthritis and systemic lupus erythematosus. iC3b levels may also be elevated in body fluids from other patients in which complement activation is known to occur, e.g., from patients with infections, burns, myocardial infarctions, glomerulonephritis, and acute respiratory distress syndrome. The correlation between iC3b levels and the clinical status or prognosis for patients with these and other diseases remains to be determined and is a question of potential significance to the biomedical community. The Quidel iC3b Enzyme Immunoassay provides a rapid, non-radioactive, highly specific and quantitative procedure for measuring this product of C3 activation. It may also be used as a research tool to monitor the generation of iC3b in vitro. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2020 | ELISA |
Human |
Plasma |
||
2021 | ELISA |
Human |
Serum |
Aspergillus incubated |
|
Complement activation by bisretinoid constituents of RPE lipofuscin. |
2009 | ELISA |
Human |
Serum |
|
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro |
2011 | ELISA |
Human |
Plasma |
|
2013 | ELISA |
Human |
CSF |
||
C4d deposits on the surface of RBCs in trauma patients and interferes with their function |
2014 | ELISA |
Human |
Serum |
Trauma |
2014 | ELISA |
Human |
Serum |
HCV |
|
quantitative lateral flow assay to detect complement activation in blood. |
2015 | ELISA |
Human |
Plasma |
|
Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis |
2014 | ELISA |
Human |
CSF |
Listeria meningitis |
2017 | ELISA |
Human |
Serum |
||
2018 | ELISA |
Human |
Plasma |
Age-Related Macular Degeneration |
|
2018 | ELISA |
Human |
Plasma |
Alzheimer's Disease |